Japan first to approve Roche’s tumour-agnostic medicine Rozlytrek

Roche’s Rozlytrek is a tumour-agnostic once-daily oral drug for certain cancers. Credit: F. Hoffmann-La Roche.



  • personalised medicine Rozlytrek